Structural Pharmacology of Bufotenine Derivatives in Activating the 5-HT 1A Receptor for Therapeutic Potential in Depression and Anxiety
Research – January 01, 2025
Source: OpenAlex
Summary
Bufotenine derivatives, particularly 5-OH-DMT and 5-MeO-DMT, demonstrate significant antidepressant and anxiolytic effects, with behavioral tests on mice showing promising results. Structural analysis revealed that these compounds interact uniquely with the 5-HT 1A receptor, crucial for treating depression and anxiety. Notably, 5-OH-DMT exhibited a distinct binding pattern, suggesting its potential for therapeutic use without hallucinogenic side effects. This work highlights the importance of understanding receptor interactions to develop next-generation nonhallucinogenic treatments targeting mental health disorders.
Abstract
The 5-HT 1A receptor is a critical target in the treatment of depression and anxiety. Bufotenine derivatives, such as 5-methoxy- N , N -dimethyltryptamine (5-MeO-DMT), 5-hydroxy- N , N -dimethyltryptamine (5-OH-DMT), and 5-hydroxy- N , N , N -dimethyltryptamine—derived from traditional Chinese medicine—have shown antidepressant potential. However, the structural basis of their interaction with 5-HT 1A and their pharmacological profiles remain incompletely understood. This study investigated bufotenine derivatives acting on multiple serotonin receptors, highlighting 5-HT 1A as a key mediator of antidepressant effects while recognizing 5-HT 2A as primarily responsible for hallucinogenic outcomes, to identify candidates with therapeutic efficacy but reduced hallucinogenic liability. We determined the cryo-electron microscopy structures of 5-HT 1A bound to selected bufotenine derivatives. Functional assays in mice, including behavioral tests and receptor activation studies, were used to evaluate the antidepressant of each compound. Structural analysis revealed that all bufotenine derivatives engage conserved motifs within the 5-HT 1A binding pocket, with 5-OH-DMT displaying a distinct interaction pattern. Behavioral assays showed that 5-OH-DMT and 5-MeO-DMT retained strong antidepressant and anxiolytic effects. These pharmacological differences correlate with their unique receptor binding conformation. This study delineated the structural pharmacology of bufotenine derivatives at the 5-HT 1A receptor, identifying 5-OH-DMT and 5-MeO-DMT as promising antidepressant and anxiolytic candidates. The findings establish a molecular framework for the development of next-generation nonhallucinogenic therapeutics aimed at 5-HT 1A .